2-alkyl-19-nor-vitamin D compounds

Details 2-alkyl-19-nor-vitamin D compounds 2-alkyl-19-nor-vitamin D compounds

1997-03-17

1999-08-31

Dees, Jose' G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

552653, A01N 4500, C07C40100

Patent

active

059454105

ABSTRACT:
This invention provides a novel class of vitamin D related compounds, namely, the 2-alkyl-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: ##STR1## where Y.sub.1 and Y.sub.2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R.sub.6 is selected from the group consisting of alkyl, hydroxyalkyl and fluoroalkyl, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 2-substituted compounds are characterized by low intestinal calcium transport activity and high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.

REFERENCES:
patent: 4666634 (1987-05-01), Miyamoto et al.
patent: 5086191 (1992-02-01), DeLuca et al.
patent: 5237110 (1993-08-01), DeLuca et al.
patent: 5246925 (1993-09-01), DeLuca et al.
patent: 5536713 (1996-07-01), DeLuca et al.
patent: 5587497 (1996-12-01), DeLuca et al.
Chemical Abstracts, XP-002066055, vol. 121, No. 21, Nov. 21, 1994.
Posner et al., 2-Fluoroalkyl A-Ring Analogs of 1,25-(OH).sub.2 D3. J. Org. Chem., 60 (14), 4617-28, 1995.
Slatopolsky, E. et al., A New Analog of Calcitriol, 19-nor-1,25-(OH).sub.2 D2 Suppresses Parathyroid Harmone Secretion in Uremic Rats in the Absence of Hypercalcemia, Am. J. Kidney Dis., 26(5), 852-60, 1995.
Posner et al, "Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1.alpha.,2.alpha.,25-Trihydroxyvitamin D.sup.3 ", J. Org. Chem. 56, pp. 4339-4341, Apr. 15, 1991.
"Chemistry of Synthetic High Polymers", Chemical Abstracts, vol. 110, No. 10, Mar. 6, 1989.
Okano et al, "Regulatory Activities of 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-Dihydroxy-Vitamin D.sub.3. A Novel Synthetic Vitamin D.sub.3 Derivative, on Calcium Metabolism", Biochemical and Biophysical Research Communications, vol. 163, No. 3, pp. 1444-1449, Sep. 29, 1989.
Bouillon et al, "Biologic Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D.sub.3 ", Bioactivity of 19-Nor-Pre D, vol. 8, No. 8, pp. 1009-1015, 1993.
Sarandeses et al, "Synthetic of 1.alpha.,25-Dihydroxy-19-Norprevitamin D.sub.3 ", Tetrahedron Letters, pp. 5445-5448, Apr. 1992.
Perlman et al, "1.alpha.,25-Dihydroxy-19-Nor-Vitamin D.sub.3. A Novel Vitamin D-Related Compound with Potential Therapeutic Activity", Tetrahedron Letters, vol. 31, No. 13, pp. 1823-1824, Feb. 1990.
Baggiolini et al, "Stereocontrolled Total Synthesis of 1.alpha.,25-Dihydroxycholecalciferol and 1.beta.,25-Dihydroxyerocalciferol", J. Org. Chem., 51, pp. 3098-3108, 1986.
Kiegel et al, "Chemical Conversion of Vitamin D.sub.3 to its 1,25-Dihydroxy Metabolite", Tetrahedron Letters, vol. 31, No. 43, pp. 6057-6060, 1991.

Affiliated with

Also associated with

Rating

2-alkyl-19-nor-vitamin D compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-alkyl-19-nor-vitamin D compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-alkyl-19-nor-vitamin D compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2426562